Industry
Biotechnology
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Loading...
Open
3.49
Mkt cap
324M
Volume
786K
High
3.49
P/E Ratio
-1.27
52-wk high
8.88
Low
3.14
Div yield
N/A
52-wk low
3.14
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 3:42 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:03 am
Portfolio Pulse from Avi Kapoor
August 20, 2024 | 2:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 4:59 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 5:21 pm
Portfolio Pulse from Vandana Singh
August 14, 2024 | 4:29 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 4:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.